Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NOTCH2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

NOTCH2 mutation	Non Small Cell Lung Cancer	NOTCH2 mutation	Non Small Cell Lung Cancer	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
NOTCH2 mutation	Non Small Cell Lung Cancer	NOTCH2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NOTCH2 mutation	Diffuse Large B Cell Lymphoma	NOTCH2 mutation	Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3
NOTCH2 mutation	Triple Negative Breast Cancer	NOTCH2 mutation	Triple Negative Breast Cancer	PF-03084014 Sensitive: D – Preclinical PF-03084014 Sensitive : D	PF-03084014 Sensitive: D – Preclinical PF-03084014 Sensitive : D